ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly deferred tax assets ($M) ($M)
Quarterly figures from Eli Lilly's filings and investor materials
Latest, Q2 2026
10,028
Period ended Jun 30, 2026
Change on a year earlier
+6.4%
9,427 in Q2 2025
History
32 quarters
Since Q4 2017
Sources
30
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 10,028 | +6.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 11,350 | +32.4% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 9,959 | +24.5% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 8,963 | +21.2% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 9,427 | +41.7% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 8,573 | +52.2% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 8,001 | +46.1% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 7,392 | +61.6% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 6,655 | +74.9% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 5,634 | +65.4% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,477 | +96.1% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 4,575 | +91.9% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 3,806 | +60.5% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,407 | +38.2% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,793 | +12.2% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2022 | Sep 30, 2022 | 2,384 | -9.2% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2022 | Jun 30, 2022 | 2,372 | -11.3% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 2,465 | -7.0% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 2,489 | -12.1% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 2,626 | +2.8% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2021 | Jun 30, 2021 | 2,675 | +7.8% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 2,650 | +7.2% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 2,830 | +10.0% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2020 | Sep 30, 2020 | 2,555 | +5.9% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2020 | Jun 30, 2020 | 2,482 | -1.0% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 2,472 | -1.6% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,573 | -1.6% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 2,413 | – | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,507 | – | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,511 | – | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,614 | +124.1% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,166 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Deferred tax assets ($M) ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/fin_dta
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.